Thrombophilia testing in the era of direct oral anticoagulants.

APS DOAC DOAC-Stop VTE antiphospholipid syndrome direct oral anticoagulants thrombophilia thrombophilia testing venous thromboembolism

Journal

Clinical medicine (London, England)
ISSN: 1473-4893
Titre abrégé: Clin Med (Lond)
Pays: England
ID NLM: 101092853

Informations de publication

Date de publication:
Sep 2021
Historique:
medline: 1 9 2021
pubmed: 1 9 2021
entrez: 10 4 2024
Statut: ppublish

Résumé

Venous thromboembolism (VTE) is increasingly recognised in primary and secondary care practice. The arrival of direct oral anticoagulants (DOACs) has made the management of VTE easier and more convenient. Some patients established on DOACs may need screening for underlying thrombophilias as certain thrombophilic conditions are known to confer a higher thrombosis risk, although the guidelines for when and how to test for a thrombophilia, especially in a patient taking a DOAC, are unclear. This literature review aims to examine when thrombophilia screening should take place in a patient already taking a DOAC, the effect of DOACs on thrombophilia tests, and analyse whether DOACs are safe and effective in both inherited and acquired thrombophilias.

Identifiants

pubmed: 38594851
pii: S1470-2118(24)03068-9
doi: 10.7861/clinmed.2020-1008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e487-e491

Informations de copyright

Copyright © 2021 © 2021 THE AUTHORS. Published by Elsevier Limited on behalf of the Royal College of Physicians. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Jennifer Darlow (J)

Manchester Royal Infirmary, Manchester, UK; equal first authors. Electronic address: jenny.wilson@doctors.org.uk.

Holly Mould (H)

University of Manchester, Manchester, UK; equal first authors.

Classifications MeSH